Using real world evidence to inform decision-making across the drug development lifecycle is contingent upon the availability of high-quality de-identified data. Only Privacy Analytics can provide risk-based solutions that utilize world-class expertise to provide quality data, scalability, automation and privacy protection.
Different types of patient data require greater privacy controls. Key to RWE efforts is balancing privacy protection and use.
Using Real World Data Starts with Privacy
With the cost of pharmaceutical health expenditures mounting, leading biopharmaceutical companies are turning to RWE to show healthcare payers the return on investment that medications can provide. Beyond pharmacovigilance, RWE is now being used in innovative ways to supplement to the learning from clinical trials and inform decisions about labeling, pricing and market access.
Realizing this opportunity requires de-identified patient data can provide meaningful analysis while maintaining individual privacy.
Early Stage R&D
Clinical Trials
Commercial
“With this system, we keep the quality of the data and bring timely and accurate data insights to the healthcare industry without having to put patient privacy at risk. The data is much richer than what we had access to before.”
Richard Borelli, Principal of Commercial Effectiveness Services,
IMS Brogan
